Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 9, 2008, Pages 1468-1473

  Gonsalves, A ^a   Carrier, M ^a,b   Wells, P S ^a,b,c   McDiarmid, S A ^a   Huebsch, L B ^a,b,c   Allan, David S ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Ambulatory care; Hematopoietic transplantation; Incidence; Pulmonary embolism; Thrombosis

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANADA; CATHETER THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LEUKEMIA; LIVER VENOOCCLUSIVE DISEASE; LUNG EMBOLISM; LUNG VENTILATION PERFUSION RATIO; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYELOMA; OUTPATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; CATHETERIZATION, CENTRAL VENOUS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; VENOUS THROMBOEMBOLISM;

EID: 49849087179     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.03077.x     Document Type: Article

References (31)

1. Gezcy CL. Induction of macrophage procoagulant by products of activated lymphocytes. Haemostasis 1984; 14: 400-11.
2. Tsakiris DA, Marbet GA, Tichelli A, Gratwohl A, Speck B. Activation of endothelium-dependent hemostatic factors following bone marrow transplantation. Schweiz Med Wochenschr 1995; 125: 416-19.
3. Nemerson Y. Tissue factor and hemostasis. Blood 1988; 71: 1-8.
4. Kaufman PA, Jones RB, Greenberg CS, Peters WP. Autologous bone marrow transplantation and factor XII, factor VII and protein C deficiencies: report of a new association and its possible relationship to endothelial cell injury. Cancer 1990; 66: 515-21.
5. Barron MA, Doyle J, Zlotkin S. Vitamin K deficiency in children pre-bone marrow transplantation. Bone Marrow Transplant 2006; 37: 151-4.
6. Verheij M, Dewit LG, Boomgaard MN, Brinkman HJ, van Mourik JA. Ionizing radiation enhances platelet adhesion to the extracellular matrix of endothelial cells by an increase in the release of von Willebrand factor. Radiat Res 1994; 137: 202-7.
7. Seeber C, Hiller E, Holler E, Kolb HJ. Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF-a)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT). Thromb Res 1992; 66: 373-83.
8. Vannucchi AM, Rafanelli D, Longo G, Bosi A, Guidi S, Saccardi R, Filimberti E, Cinotti S, Grossi A, Morfini M, Rossi-Ferrini P. Early haemostatic alterations following bone marrow transplantation: A prospective study. Haematologica 1994; 79: 519-25.
9. Catani L, Gugliotta L, Vianelli N, Nocentini F, Baravelli S, Bandini G, Cirio TM, Tura S. Endothelium and bone marrow transplantation. Bone Marrow Transplant 1996; 17: 277-80.
10. Haire WD. Antithrombin III in hematopoietic stem cell transplantation. Semin Thromb Haemost 1997; 23: 591-601.
11. Brandao LR, Kletzel M, Boulad F, Kurtzberg J, Maloney K, Fligman I, Sison CP, Dimichele D. A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 1240-6.
12. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C, Zhang H, Huebsch L. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723-9.
13. Wells PS, Anderson DR, Rodger MA, Stiell I, Dreyer JF, Barnes D, Forgie M, Kovacs G, Ward J, Kovacs MJ. Excluding pulmonary embolism at the bedside without diagnostic imaging: Management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and D-dimer. Ann Intern Med 2001; 135: 98-107.
14. Bearman SI, Appelbaum FR, Buckner D, Petersen FB, Fisher LD, Clift RA, Thomas ED. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-8.
15. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
16. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9.
17. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 338S-400S.
18. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Janhanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Frnacis CW. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505.
19. Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006; 37: 677-86.
20. Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention. Blood 2008; DOI 10.1182/blood-2007-10-117051.
21. Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E, Holler E, Kolb HJ. Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-9.
22. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-90.
23. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-46.
24. Niers TM, Di Nisio M, Klerk CP, Baarslag HJ, Büller HR, Biemond BJ. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: A randomized, placebo-controlled study. J Thromb Haemost 2007; 5: 1878-82.
25. Carrier M, Tay J, Fergusson D, Wells PS. Thromboprophylaxis for catheter-related thrombosis in patients with cancer: A systemic review of the randomized controlled trials. J Thromb Haemost 2007; 5: 2552-4.
26. Akl EA, Karmath G, Yosuico V, Kim SY, Barba M, Sperati F, Cook D, Schünemann HJ. Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. Cochrane Database Syst Rev 2007; 18: CD006468.
27. Chaukiyal P, Nautiyal A, Radhakrishnan S, Singh S, Navaneethan SD. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost 2008; 99: 38-43.
28. Pihusch M, Lohse P, Reitberger J, Hiller E, Andreesen R, Kolb HJ, Holler E, Pihusch R. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 2004; 78: 911-18.
29. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-56.
30. Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006; 12: 252-66.
31. Biedermann BC, Sahner S, Gregor M, Tsakiris DA, Jeanneret C, Pober JS, Gratwohl A. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet 2002; 359: 2078-83.